v3.26.1
Segment Information (Tables)
12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Reconciles Segment Direct Profit or Loss

The following table reconciles segment direct profit or loss to the Company’s consolidated results:

 

Year Ended
December 31,

 

(in thousands)

2025

 

 

2024

 

Research and development:

 

 

 

 

 

QTORIN rapamycin for microcystic LM

$

4,755

 

 

$

1,929

 

QTORIN rapamycin for microcystic LM - Government grant income

 

(987

)

 

 

(141

)

QTORIN rapamycin for cutaneous VM

 

2,224

 

 

 

296

 

QTORIN CMC

 

6,953

 

 

 

1,601

 

Non-program specific and unallocated research and development expenses:

 

 

 

 

 

Salaries and stock-based compensation

 

6,643

 

 

 

2,810

 

Consultants

 

1,910

 

 

 

1,040

 

Other

 

1,343

 

 

 

616

 

Total research and development

$

22,841

 

 

$

8,151

 

General and administrative:

 

 

 

 

 

Salaries and stock-based compensation

$

7,827

 

 

$

1,935

 

Consultants

 

3,285

 

 

$

2,961

 

Other

 

4,650

 

 

$

1,048

 

Total general and administrative

$

15,761

 

 

$

5,944

 

Loss from operations

$

(38,602

)

 

$

(14,095

)